
Danish biotech firm Bavarian Nordic will begin a phase III trial of its Covid-19 vaccine in June, 2022, according to database Clinical Trials.
To test the company’s candidate, ABNCov2, Bavarian will recruit patients who have already received Comirnaty (Pfizer/Biontech), Spikevax (Moderna), Vaxzevria (Astrazeneca), Janssen Covid-19 vaccine (Johnson & Johnson) or other approved vaccines in the EU and US, according to the registration.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app